Performance of BinaxNOW for diagnosis of malaria in a U.S. hospital
Journal of Clinical Microbiology, 07/03/2012
DiMaio MA et al. – Excluding patients on anti–malarial therapy, sensitivity was 92.9%. Importantly, BinaxNOW initially misclassified a case of P. falciparum as non–falciparum. These results support the judicious use of BinaxNOW in screening of malaria suspects in non–endemic areas.